Immuron Limited
Officers & Directors
Paul Brennan, age 64, has served as Non-Executive Chairman since July 1, 2023, and has been a board member since March 2022. He holds an MBA from Swinburne University, a Bachelor of Science from the University of New England, and nursing certificates. Brennan was CEO of PolyNovo Limited from 2015 to 2021 and has experience in health systems and multinational companies. Daniel Pollock, age 64, has been a Non-Executive Director since October 2012. He is a lawyer admitted in Scotland and Australia, operates his own legal firm, and serves as executive director and co-owner of Great Accommodation Pty Ltd. Ravi Savarirayan, age 58, has been a Non-Executive Director since April 2017. He holds a Doctor of Medicine from the University of Melbourne and other medical qualifications. Savarirayan is a consultant clinical geneticist, professor, research group leader, and has held leadership roles in genetics societies. Jeannette Joughin, age 62, has been a Non-Executive Director since June 1, 2024. She holds a Bachelor of Science (Honours) and a PhD.
Immuron Limited currently has 12 employees.
News about Immuron Limited Key Personnel |
Immuron Requests Pre-IND Meeting with FDA for IMM-529 and Shares Soar 17.82% in Five Trading Days
Melbourne, Australia - Immuron Limited (ASX: IMC; NASDAQ: IMRN), a leading global biopharmaceutical company based in Australia, is excited to announce the submission of a pre-IND (investigational new drug) application to the United States Food and Drug Administration (FDA) for IMM-529, a groundbreaking therapeutic candidate. This remarkable achievement marks a significant milestone in Immuron s mission to develop innovative solutions for improving human health and solidifies its position as a frontrunner in the biopharmaceutical industry.
The pre-IND application showcases Immuron s commitment to advancin...
|
|
